GSK, India’s Regulus Join To Make RNA-Based Drugs
This article was originally published in PharmAsia News
GlaxoSmithKline has signed an agreement with India's Regulus Therapeutics, in a deal that could be worth as much as $600 million to the Indian biotech. The deal with GSK is for research into the Regulus specialty of RNA technology to discover microRNA-based drugs. The intention is to develop drugs to treat rheumatoid arthritis, inflammatory bowel disease and other diseases resulting from chronic inflammation. The deal gives GSK the option of licensing certain drug candidates. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.